MB-07811 |
| Catalog No.GC70323 |
MB-07811(VK - 2809) est un pro - médicament hepdirect actif par voie orale de mb07344, un Agoniste bêta du récepteur des hormones thyroïdiennes ciblant le foie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 852948-13-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MB-07811 (VK-2809) is potential for liver targeting with a low affinity for thyroid hormone receptors (TRβ Ki=14.6 ± 0.5 μM; TRα Ki=12.5 ± 0.6 μM)[2].
MB-07811 (VK-2809) (0.3-30 mg/kg; orally once daily for 14 days) reduces cholesterol and triglycerides in diet-induced obese mice[2].
References:
[1]. Cable EE, et al. Reduction of hepatic steatosis in rats and mice after treatment with aliver-targeted thyroidhormone receptor agonist. Hepatology. 2009 Feb;49(2):407-17.
[2]. Erion MD, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15490-5.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *